Gossamer Bio, Inc. Announces Major Debt Exchange and Material Financial Agreements
Key Points from June 2026 SEC Filing
- Debt Exchange Completed: Gossamer Bio, Inc. has successfully completed an early tender of its Existing Convertible Notes, exchanging them for new financial instruments.
- New Securities Issued: The company issued:
- \$65,174,000 in aggregate principal amount of New Convertible Notes
- 254,150,441 New Shares
- 33,402,727 Prefunded Warrants
- 135,789,000 Purchase Warrants
- High Participation Rate: 90.526% of the previously outstanding Existing Convertible Notes were tendered and cancelled.
- Minimum Liquidity Covenant: The company is required to maintain a minimum liquidity level of \$40 million, with provisions to reduce this requirement upon completion of equity raises and FDA milestones.
- Shareholder Approval Required: Certain securities and conversions are subject to shareholder approval, including increases in authorized common stock and approval for issuance under Nasdaq rules.
- Material Definitive Agreements Terminated: The Transaction Support Agreement related to the exchange offer was automatically terminated on the settlement date.
- Regulatory & Price-Sensitive Disclosure: The new securities are not registered under the Securities Act. Any offer, sale, or solicitation of these securities is subject to strict regulatory limitations.
Important Shareholder Considerations
- Potential Dilution: The issuance of over 254 million new shares, plus up to 135.8 million shares via Purchase Warrants and 33.4 million Prefunded Warrants, represents substantial potential dilution to existing shareholders.
- Conversion and Repurchase Features:
- New Convertible Notes can be converted into common stock, potentially increasing dilution.
- Mandatory conversion provisions exist under certain circumstances.
- Upon a “Fundamental Change” (such as acquisition of >50% of shares or delisting), holders may require the company to repurchase their Notes at 100% of principal plus accrued interest.
- Liquidity Requirements:
- Minimum liquidity covenant is \$40 million, reduced to \$20 million or \$10 million if equity raises or FDA milestones are met, and \$0 if \$150 million is raised.
- Failure to meet liquidity requirements could trigger events of default or accelerate obligations.
- Voting Agreements: Supporting Noteholders agreed not to transfer their new shares until after the special shareholder meeting, which may temporarily restrict trading in these shares.
- Customary Negative Covenants: The New Convertible Notes Indenture includes restrictions on additional debt, liens, mergers, related party transactions, and asset disposals, limiting the company’s financial flexibility.
- Regulatory Risk: The offered securities are unregistered, and trading or transfer is subject to legal restrictions and legends, including lock-up periods and Rule 144 limitations.
- Forward-Looking Risks: The company warns that completion of the exchange offer, achievement of FDA milestones, and realization of benefits are subject to risks and may not occur as expected.
Material Agreements & Potential Price Impact
- Debt Restructuring: The exchange of existing convertible notes for new instruments, including new equity and warrants, materially changes the capital structure and may affect valuation.
- Potential for Share Price Movement:
- Large-scale issuance of new shares and warrants may depress share price due to dilution.
- Minimum liquidity covenant provides a safety net but also signals financial risk if not met.
- Mandatory conversion and repurchase at fundamental change events may create volatility.
- Shareholder approval needed for conversion and additional stock issuance introduces uncertainty.
- Termination of Agreements: The automatic termination of the Transaction Support Agreement and the cancellation of old notes signal completion of the restructuring process.
- Press Release: The company publicly announced these developments, which could impact market sentiment.
Forward-Looking Statement & Risks
- The company cautions that actual results may differ due to risks and uncertainties, including the ability to complete the exchange offer, achieve liquidity targets, obtain FDA approvals, and secure shareholder approval.
- Investors should consider risks described in prior filings, including Form 10-K, and should not place undue reliance on forward-looking statements.
Disclaimer: This article is for informational purposes only and does not constitute investment advice or an offer to buy or sell securities. All information is based on publicly available filings and company disclosures as of June 2026. Readers should consult their own financial advisors and review official SEC filings before making investment decisions. All forward-looking statements are subject to risks and uncertainties, and Gossamer Bio, Inc. undertakes no obligation to update such statements.
